t-mab 150 mg pulbere pentru soluţie perfuzabilă
nativita srl - trastuzumabum - pulbere pentru soluţie perfuzabilă - 150 mg
herzuma 150 mg pulbere pentru concentrat pentru soluţie perfuzabilă
celltrion healthcare co. ltd. - trastuzumabum - pulbere pentru concentrat pentru soluţie perfuzabilă - 150 mg
herceptin 600 mg/5 ml soluţie injectabilă
f.hoffmann-la roche, ltd. - trastuzumabum - soluţie injectabilă - 600 mg/5 ml
herzuma 440 mg pulbere şi solvent pentru concentrat pentru soluţie perfuzabilă
celltrion healthcare co. ltd. - trastuzumabum - pulbere şi solvent pentru concentrat pentru soluţie perfuzabilă - 440 mg
ogivri 150 mg pulbere pentru concentrat pentru soluţie perfuzabilă
mylan s.a.s. - trastuzumabum - pulbere pentru concentrat pentru soluţie perfuzabilă - 150 mg
zercepac 150 mg pulbere pentru concentrat pentru soluţie perfuzabilă
accord healthcare s.l.u. - trastuzumabum - pulbere pentru concentrat pentru soluţie perfuzabilă - 150 mg
herwenda
sandoz gmbh - trastuzumab - breast neoplasms; stomach neoplasms - agenți antineoplazici - treatment of metastatic and early breast cancer and metastatic gastric cancer (mgc).
phesgo
roche registration gmbh - pertuzumab, trastuzumab - sânii neoplasme - agenți antineoplazici - early breast cancer (ebc)phesgo is indicated for use in combination with chemotherapy in:the neoadjuvant treatment of adult patients with her2-positive, locally advanced, inflammatory, or early stage breast cancer at high risk of recurrencethe adjuvant treatment of adult patients with her2-positive early breast cancer at high risk of recurrencemetastatic breast cancer (mbc)phesgo is indicated for use in combination with docetaxel in adult patients with her2-positive metastatic or locally recurrent unresectable breast cancer, who have not received previous anti-her2 therapy or chemotherapy for their metastatic disease.
bortezomib sandoz 1 mg
synthon hispania s.l. - spania - bortezomibum - pulb. pt. sol. inj. - 1mg - alte antineoplazice alte antineoplazice
bortezomib sandoz 3,5 mg
synthon hispania s.l. - spania - bortezomibum - pulb. pt. sol. inj. - 3,5mg - alte antineoplazice alte antineoplazice